At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 152 target
Drug / intervention
X-396 capsuledrug
Likely dose
X-396 capsule 225mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
In Brief
A Phase 2 clinical trial evaluating X-396 capsule for Non-Small Cell Lung Cancer. Targeting 152 participants across 4 sites.
Detailed Summary
The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartSep 2017
Primary CompletionMar 2020
Study CompletionDec 2023
TodayJul 2026
First PostedJul 12, 2017
Enrollment StartSep 28, 2017
Primary CompletionMar 9, 2020
Study CompletionDec 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 9.0 years ago
Interventions
X-396 capsuledrug
225mg once daily